上海医药苹果酸司妥吉仑片上市许可申请获批

Core Insights - Shanghai Pharmaceuticals announced the approval of its drug, SPH3127 tablets, by the National Medical Products Administration (NMPA) [1] - SPH3127 is a new generation oral non-peptide small molecule renin inhibitor, designed to treat primary hypertension by directly inhibiting renin [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyin Pharmaceutical Factory, received the drug registration certificate for SPH3127 [1] - The approval signifies a significant milestone for the company in expanding its product portfolio in the hypertension treatment market [1] Industry Summary - SPH3127 targets the overactivation of the renin-angiotensin-aldosterone system (RAAS), which is a key factor in hypertension [1] - The introduction of new hypertension treatments like SPH3127 reflects ongoing innovation in the pharmaceutical industry aimed at addressing cardiovascular diseases [1]